Baicalein blocked cervical carcinoma cell proliferation by targeting CCND1 via Wnt/β-catenin signaling pathway
Source abstract
Abstract
The purpose of this study was to investigate the inhibitory effect of baicalein on the proliferation of cervical carcinoma cells and stimulate cervical carcinoma cells with baicalein. MTT method was used to observe cell proliferation. Flow cytometry was used to observe cell cycle, and gene technology was used to observe the expression of corresponding genes at the level of gene and protein. β-catenin activity was assessed using Western blot and ChIP. Baicalein suppressed cervical carcinoma cell HeLa proliferation by enhancing the activity of caspase-3. Baicalein blocked cell cycle at G0/G1 stage by inhibiting the expression of some genes. At the same time, it can prevent the nuclear translocation of β-catenin and inhibit the activity of Wnt. When the Wnt signaling pathway is increased, the proliferation of HeLa cells is inhibited, and apoptosis is promoted in this way. In conclusion, it indicated that baicalein inhibits cervical carcinoma progression by targeting CCND1 via Wnt/β-catenin signaling pathway.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Flavonoids in Medical Research · Cancer-related Molecular Pathways · Axon Guidance and Neuronal Signaling
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Obstetrics and Gynecology, The Affiliated TCM Hospital of South West Medical University
School of Medical Information and Engineering, Southwest Medical University
Medicine Experimental Center, The Affiliated Hospital of Southwest Medical University
Funding
Luzhou Science and Technology Bureau Project · Liangshan Science and Technology Bureau Project · Project of Sichuan Traditional Chinese Medicine Administration · Luzhou Science and Technology Bureau-Southwest Medical University Joint Project
References (33)
Show source-provided references
1. 10.1016/j.bbadis.2011.10.00510.1016/j.bbadis.2011.10.005 ↗
2. 10.3892/mmr.2014.288510.3892/mmr.2014.2885 ↗
3. 10.1016/j.ejphar.2009.09.03310.1016/j.ejphar.2009.09.033 ↗
4. 10.1016/j.fct.2009.04.01410.1016/j.fct.2009.04.014 ↗
5. 10.1179/1973947814Y.000000017710.1179/1973947814Y.0000000177 ↗
6. 10.3390/ijms1710168110.3390/ijms17101681 ↗
7. 10.1038/nrm71410.1038/nrm714 ↗
8. 10.1038/nrd290710.1038/nrd2907 ↗
9. 10.1080/15384101.2018.152659810.1080/15384101.2018.1526598 ↗
10. 10.1111/cas.1397610.1111/cas.13976 ↗
11. 10.1002/path.531310.1002/path.5313 ↗
12. 10.1186/s12885-016-2775-210.1186/s12885-016-2775-2 ↗
13. 10.1016/j.immuni.2006.12.00710.1016/j.immuni.2006.12.007 ↗
14. 10.1002/biof.145510.1002/biof.1455 ↗
15. 10.1186/2045-824X-3-2810.1186/2045-824X-3-28 ↗
16. 10.4149/neo_2016_50710.4149/neo_2016_507 ↗
17. 10.1172/JCI7152610.1172/JCI71526 ↗
18. 10.1038/nprot.2006.9810.1038/nprot.2006.98 ↗
19. 10.1158/1541-7786.MCR-09-037310.1158/1541-7786.MCR-09-0373 ↗
20. 10.1016/j.ctrv.2010.02.00710.1016/j.ctrv.2010.02.007 ↗
21. 10.4161/cc.9.10.1147410.4161/cc.9.10.11474 ↗
22. 10.1073/pnas.21251949910.1073/pnas.212519499 ↗
23. 10.1586/era.11.19410.1586/era.11.194 ↗
24. 10.1073/pnas.112006810910.1073/pnas.1120068109 ↗
25. 10.18632/oncotarget.66710.18632/oncotarget.667 ↗
26. 10.1053/hupa.2002.3072310.1053/hupa.2002.30723 ↗
27. 10.1073/pnas.061029910410.1073/pnas.0610299104 ↗
28. 10.3390/genes902010910.3390/genes9020109 ↗
29. 10.3389/fonc.2013.0008510.3389/fonc.2013.00085 ↗
30. 10.1177/074873041774591310.1177/0748730417745913 ↗
31. 10.1021/jf063299z10.1021/jf063299z ↗
32. 10.1016/j.phymed.2009.07.00310.1016/j.phymed.2009.07.003 ↗
33. 10.3892/or.2015.378610.3892/or.2015.3786 ↗